Evaluation of alpha-defensins as a marker of severity in chronic obstructive pulmonary disease.

IF 1.3 Q4 RESPIRATORY SYSTEM Lung India Pub Date : 2024-07-01 Epub Date: 2024-06-28 DOI:10.4103/lungindia.lungindia_395_23

Kritika Kumar, Komaldeep Kaur, Shivani Jaswal, Deepak Aggarwal, Varinder Saini

{"title":"Evaluation of alpha-defensins as a marker of severity in chronic obstructive pulmonary disease.","authors":"Kritika Kumar, Komaldeep Kaur, Shivani Jaswal, Deepak Aggarwal, Varinder Saini","doi":"10.4103/lungindia.lungindia_395_23","DOIUrl":null,"url":null,"abstract":"Background: Defensins are key effector molecules of innate immunity that can contribute towards the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD). The present study was conducted to investigate the role of alpha-defensins in patients with COPD by quantifying serum and sputum samples.Methods: A total of 180 patients were enrolled and divided into four groups, and sputum and serum values of alpha-defensins were assessed. The sensitivity, specificity, and accuracy of sputum alpha-defensin as a diagnostic biomarker were evaluated to assess its utility in diagnosing COPD.Results: The mean value of sputum alpha-defensins was found to be statistically significant amongst the four groups (P < 0.001). The highest levels were found in subjects with AECOPD (385.76 ± 116.62 ng/mL). Sputum alpha-defensins were found to be negatively correlated with FEV 1 values (rho = -0.31, P < 0.001).Conclusion: Sputum alpha-defensins can be used as a potential marker for predicting acute exacerbation of COPD. In addition, they could serve as an indicator of disease severity in COPD patients.","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"259-264"},"PeriodicalIF":1.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302783/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung India","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/lungindia.lungindia_395_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Defensins are key effector molecules of innate immunity that can contribute towards the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD). The present study was conducted to investigate the role of alpha-defensins in patients with COPD by quantifying serum and sputum samples.

Methods: A total of 180 patients were enrolled and divided into four groups, and sputum and serum values of alpha-defensins were assessed. The sensitivity, specificity, and accuracy of sputum alpha-defensin as a diagnostic biomarker were evaluated to assess its utility in diagnosing COPD.

Results: The mean value of sputum alpha-defensins was found to be statistically significant amongst the four groups (P < 0.001). The highest levels were found in subjects with AECOPD (385.76 ± 116.62 ng/mL). Sputum alpha-defensins were found to be negatively correlated with FEV 1 values (rho = -0.31, P < 0.001).

Conclusion: Sputum alpha-defensins can be used as a potential marker for predicting acute exacerbation of COPD. In addition, they could serve as an indicator of disease severity in COPD patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估作为慢性阻塞性肺病严重程度标志物的α-防御素。

背景：防御素是先天性免疫的关键效应分子，有助于诊断和监测慢性阻塞性肺疾病（COPD）。本研究通过对血清和痰样本进行定量分析，探讨α-防御素在慢性阻塞性肺病患者中的作用：方法：共招募了 180 名患者并将其分为四组，评估痰和血清中的α-防御素值。评估痰中α-防御素作为诊断生物标志物的敏感性、特异性和准确性，以评估其在诊断慢性阻塞性肺病中的作用：结果发现，四组患者痰中α-防御素的平均值具有统计学意义（P < 0.001）。AECOPD患者的痰液α-防御素水平最高（385.76 ± 116.62 ng/mL）。痰α-防御素与 FEV 1 值呈负相关（rho = -0.31，P < 0.001）：结论：痰α-防御素可作为预测慢性阻塞性肺病急性加重的潜在标志物。结论：痰α-防御素可作为预测慢性阻塞性肺病急性加重的潜在标志物，也可作为慢性阻塞性肺病患者疾病严重程度的指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊